Are DERM insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies DERM leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / DERM / insiders

NGEN (45) MENS (33) MSLE (46) RNA (44) ⌘ Pro Terminal →

Journey Medical Corporation (DERM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Where is DERM trading relative to its 50-day, 200-day, and 52-week technical levels?

DERM last traded at $4.79 (-7.35% on volume of 142,618 shares), positioning the stock -25.97% below its 50-day simple moving average ($6.47) and -27.75% below its 200-day simple moving average ($6.63). Across its 52-week range of $4.31 to $9.56, DERM sits at the 9.1% percentile with a 14-day RSI of 40.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.19 to $5.39).

$4.79 -7.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.72

Journey Medical Corporation (DERM) carries a Roarable Rating of E (Strong Sell) with 16/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $145.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DERM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DERM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Journey Medical Corporation (NASDAQ: DERM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 16/100 at a spot price of $4.79 (-7.35% 1D, market cap $145.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, DERM ranks #1009 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DERM compare to NGEN and MENS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DERM carries a Roarable E (16/100 RQD), trailing P/E of N/A, gross margin of 65.8%, and ROIC of -19.5%. By comparison, NGEN (NervGen Pharma Corp.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $147.4M) and MENS (Jyong Biotech Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.8%, cap $142.9M). Among the 5-stock peer group, DERM leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DERM?

▼

Per DERM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001867066), Journey Medical Corporation generated $61.2M in revenue (+11.1% YoY), -$11.4M in net income, and -$12.4M in free cash flow against $94.6M in total assets and $25.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.72 (-1.51%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (16/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-19% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DERM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (16/100 Composite)

🔍 WHY DERM SCORES 16/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (31% of score)

Altman Z-Score 0.74 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 65.8% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$5.91-12.5% Next Q

Q2 (-2Q)

Grade E$5.17-3.9% Next Q

Q3 (-1Q)

Grade E$4.97-3.6% Next Q

Current

Grade E$4.79-12.7% Hist 90D α

Trajectory: E (24) → E (16)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DERM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DERM currently carries a cautious 16/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.47) and Max Pain ($5.03) forces dealer call-delta covering toward $10.04.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DERM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DERM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 18%NO 82%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

DERM Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (DERM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on DERM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DERM)

✓Walkthrough of DERM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DERM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.45%🛡️ HOLDING TREND SUPPORT

2026-11-03O $5.41H $5.41L $4.79C $4.79VOL 235.1K

RES: $9.12SUP: $4.56SMA50: $6.47SMA200: $6.63

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DERM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DERM Butterfly Map → + Track DERM →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +11.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on DERM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DERM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DERM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DERM)

Health Care Rank #1009 of 1015 ⚔️ NGEN vs DERM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DERM vs. NGEN, MENS, MSLE, RNA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Journey Medical Corporation (DERM) ranks #1009 by composite RQD confidence (16/100, grade E) and #608 by equity capitalization ($145.9M). Within this direct 5-issuer industry benchmark cohort, DERM leads on earnings valuation at N/A trailing P/E, while DERM leads on capital efficiency and profitability with -19.5% ROIC and 65.8% gross margin. MSLE currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with DERM at 16/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DERM ACTIVE Journey Medical Corporation	E	16/100	—	65.8%	-19.5%	-7.35%	$145.9M	Benchmark Subject
NGEN NervGen Pharma Corp.	D	45/100	—	—	—	-1.46%	$147.4M	/ngen-vs-derm →
MENS Jyong Biotech Ltd.	E	33/100	—	—	-28.8%	-0.53%	$142.9M	/mens-vs-derm →
MSLE Satellos Bioscience Inc.	D	46/100	—	—	—	-4.48%	$142.2M	/msle-vs-derm →
RNA Atrium Therapeutics Inc.	D	44/100	—	—	—	+3.39%	$141.5M	/rna-vs-derm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001867066 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Journey Medical Corporation (DERM) reported GAAP revenue of $61.2M (+11.1% vs. FY2024 revenue of $55.1M , and +2.6% cumulative change since FY2023) , GAAP net income of -$11.4M, operating cash flow of -$12.4M, and free cash flow of -$12.4M (-36.3% YoY). On the balance sheet, DERM closed FY2025 with $94.6M in total assets against $25.3M in total debt (Altman Z-Score: 0.74, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$61.2M	-$11.4M	-$12.4M	-$12.4M	$94.6M	$25.3M
FY2024 (FY)	2024-12-31	$55.1M	-$14.7M	-$9.1M	-$9.1M	$80.2M	$24.9M
FY2023 (FY)	2023-12-31	$59.7M	-$3.9M	$5.2M	$5.2M	—	—

3. DERM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DERM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does DERM compare to NGEN and MENS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for DERM?

Where is DERM trading relative to its 50-day, 200-day, and 52-week technical levels?

DERM last traded at $4.79 (-7.35% on volume of 142,618 shares), positioning the stock -25.97% below its 50-day simple moving average ($6.47) and -27.75% below its 200-day simple moving average ($6.63). Across its 52-week range of $4.31 to $9.56, DERM sits at the 9.1% percentile with a 14-day RSI of 40.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.19 to $5.39).

Direct Sub-Reports: DERM RQD Cockpit DERM 12M Forecast DERM Earnings & Move DERM Dividends & DRIP DERM Insiders & 13F DERM Whale Options DERM Profit Sankey DERM News & Why

ROARABLE RATING BRIEF • RQD 16/100 (E) ✓ SEC XBRL & RQD VERIFIED

DERM — Journey Medical Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Journey Medical Corporation (DERM) earns a live Roarable RQD composite score of 16/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.79 (-7.35% 1D, market capitalization $145.9M).

Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -19.5%, gross margin of 65.8%, operating margin of -13.3%, and free cash flow yield of -8.15%.
Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (4/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.74, Piotroski F-Score of 5/9, and Debt/Equity of 0.79x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Journey Medical Corporation is a NASDAQ-listed issuer classified in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $0.2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Journey Medical Corporation (DERM) reported $61.2M in annual revenue (up from $55.1M in FY2024, +11.1% YoY) and -$11.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($59.7M revenue, -$3.9M net income) through FY2025, DERM scaled operating cash flow to -$12.4M and free cash flow to -$12.4M, backed by $94.6M in total assets against $25.3M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 16/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -8.15% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $4.31 – $9.56 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -13.3% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependency mapping is therefore — Sector correlation data beyond the Beta of 1.0 is — A prospective investor should watch for any future disclosure of supplier, distributor, or licensing dependencies, since none are currently mapped.

Key Question #1: Can DERM sustain or expand its -13.3% operating margin and -19.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $61.2M and free cash flow of -$12.4M, how will capital allocation balance growth reinvestment against $25.3M in total debt?
Key Question #3: How sensitive is DERM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

DERM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Journey Medical Corporation (DERM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DERM Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 22h ago

Journey Medical Corporation Estimates – NASDAQ:DERM

TradingView report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An investment adviser reports passive ownership of 2.45M shares in Journey Medical (DERM).

Stock Titan report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Journey Medical (NASDAQ:DERM) Stock Moved Down to "Hold" by Wall Street Zen

MarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?

Yahoo Finance report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Journey Medical Corporation (DERM) Jumps 6.04% as Shares Reclaim Ground Toward $5.09 - Fair Value Gap

https://www.siam.in/ report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Journey Medical's (DERM) Buy Rating Reiterated at HC Wainwright

MarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Medexus Pharmaceuticals Inc. (MDP.TO) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Journey Medical Q3 2026 Earnings Date and Estimates

MarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DERM Bull vs. Bear Conversation Board — What's Your Call at $4.79?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DERM 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $6.26 (+21.1%)

📌 Pinned Debate

Whale 13F flow scores 12/20, suggesting institutional accumulation is more constructive than the fundamentals alone imply.

Whale 13F flow scores 12/20, suggesting institutional accumulation is more constructive than the fundamentals alone imply.. When you look under the hood at DERM, Fundamental Cash Engine is 1/20 with 65.8% gross margins and -19.5% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $9.56. My 12M target is $6.26.

EarningsSniper 🐂 BULL

@RiskArb_Desk Shorting a 3/20 institutional whale-flow stock at $5.17 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $3.93 (-24.0%)

Spot @ $5.17

ROIC of -19.5%, FCF yield of -8.15%, and an Altman Z of 0.74 point to a cash engine and balance sheet under forensic stress.

Fading this rally in DERM at $5.17. ROIC of -19.5%, FCF yield of -8.15%, and an Altman Z of 0.74 point to a cash engine and balance sheet under forensic stress.. With a beta of 1.0 and the stock sitting at $5.17 (52-wk range $4.31–$9.56), the easy multiple expansion is already priced in.